The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Aug. 29, 2017
Filed:
Nov. 19, 2012
Applicant:
Genzyme Corporation, Cambridge, MA (US);
Inventors:
Johanne Kaplan, Framingham, MA (US);
John McPherson, Framingham, MA (US);
Assignee:
GENZYME CORPORATION, Cambridge, MA (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 45/00 (2006.01); A61K 47/00 (2006.01); A61K 39/395 (2006.01); A61K 38/18 (2006.01); C07K 16/28 (2006.01); A61K 45/06 (2006.01); C07K 14/495 (2006.01); C07K 16/18 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
A61K 39/3955 (2013.01); A61K 38/1841 (2013.01); A61K 39/39541 (2013.01); A61K 45/06 (2013.01); C07K 14/495 (2013.01); C07K 16/18 (2013.01); C07K 16/28 (2013.01); C07K 16/2809 (2013.01); C07K 16/2893 (2013.01); A61K 2039/505 (2013.01); C07K 2317/73 (2013.01);
Abstract
Novel methods for treating patients with autoimmune diseases are disclosed. The methods of the invention include first depleting circulating lymphocytes in the mammal, e.g., by administering anti-thymocyte antibody, and then, during the course of repopulation, administering to the mammal a therapeutically effective amount of latent TGF-β and/or another agent that promotes expansion of regulatory T cells. In certain aspects, the disclosed process results in improved kidney function and survival rates.